Dutch Cangrelor Registry

Isala250 enrolled

Overview

Cangrelor is a fast and directly acting platelet aggregation inhibitor. It is potentially indicated for several types of patients who are undergoing PCI. A nationwide cangrelor registry has up until now not been performed and with the introduction of cangrelor in the Netherlands its efficacy and safety will be determined.

Study Type

OBSERVATIONAL

Enrollment

250

Conditions

STEMI - ST Elevation Myocardial Infarction NSTEMI - Non-ST Segment Elevation MI Coronary Artery Disease

Interventions

CangrelorDRUG

Cangrelor intravenous

Eligibility

Sex: ALLMin age: 18 YearsMax age: 110 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age ≥18 years * One of the following criteria: * Patients naïve for P2Y12 inhibition undergoing PCI * Patients with suboptimal P2Y12 inhibition undergoing PCI (patients who vomited after P2Y12 loading, out of hospital cardiac arrest (OHCA) patients with restoration of spontaneous circulation (ROSC), patients loaded with P2Y12 inhibitors though platelet inhibition still insufficient (\<2 hours after oral loading dose) * (N)STEMI patients loaded with P2Y12 inhibitors with large thrombus burden (thrombus grade 4 or 5) on initial coronary angiography (CAG) and undergoing primary PCI with expected insufficient P2Y12 inhibition Exclusion Criteria: * Patients on current/chronic treatment with P2Y12 inhibitors * Patients (pre) treated with a GPI * Patients with recent major bleeding complications or contraindication to dual antiplatelet therapy: * hypersensitivity or allergy to and known contra-indication for aspirin, clopidogrel, ticagrelor or cangrelor * history of major clinical bleeding or known coagulopathy * active bleeding * history of intracerebral mass, aneurysm, arteriovenous malformation, or hemorrhagic stroke * known severe liver dysfunction * Patients that received any organ transplant or are on a waiting list for any organ transplant * Patients undergoing dialysis * Pregnant or lactating female * Patients currently participating in another investigational drug or device study

Locations (1)

R.S. Hermanides

Zwolle, Overijssel, Netherlands

Outcomes

Primary Outcomes

NACE

The primary efficacy and safety endpoint is 48 hours Net Adverse Clinical Events (NACE), which is a composite endpoint of all-cause death (including cardiac death), recurrent myocardial infarction, target vessel revascularization, stroke, definite or probable stent thrombosis and bleeding (BARC type 2-5).

Time frame: 48 hours

Secondary Outcomes

NACE 30 days

Net Adverse Clinical Events (NACE), which is a composite endpoint of all-cause death (including cardiac death), recurrent myocardial infarction, target vessel revascularization, stroke, definite or probable stent thrombosis and bleeding (BARC type 2-5).

Time frame: 30 days

All individual endpoints in-hospital

Time frame: In-hospital, mostly up to 72 hours.

All individual endpoints at 30-days

Time frame: 30 days

TIMI 3 flow post PCI based on angiographic results

TIMI 3 flow post PCI

Time frame: post-PCI, mostly up to 1 hour

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.